Prothena Corporation plc

Prothena Corporation plc

PRTANYSE / NASDAQHealthcareSmall cap

$8.22-$0.18 (-2.1%)

Last close · Data as of Nov 20, 2026

Market cap
$484.3M
P/E
-2.0x
EV / EBITDA
-1.0x
Revenue
$9.7M
Net margin
-2520.6%
ROCE
-64.5%

-18.2% over the last year

Prothena Corporation plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-3.3%
3M
-9.0%
6M
-12.1%
1Y
-18.2%
5Y
-86.0%

52-week range

Day change -$0.18 (-2.1%) from $8.40 to $8.22 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PRTA, bought on each weekday since 2021.

News & filings

What Prothena Corporation filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 244 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.72 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.

Read moreShow less

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Sector
Healthcare
Shares outstanding
53.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$484.3M
P/E
-2.0x
P/B
1.7x
EV / EBITDA
-1.0x
EV / Sales
19.1x
P/S
50.0x
52-week high
$11.51
52-week low
$7.89

Profitability

Operating margin
-1905.8%
Net margin
-2520.6%
EBITDA margin
-1896.6%
ROE
-87.0%
ROCE
-64.5%
ROA
-74.7%
Asset turnover
0.03

Growth

Revenue
$9.7M
Revenue growth, 1Y
-92.8%
Revenue CAGR, 3Y
-43.6%
Net profit growth, 1Y
99.6%
Free cash flow
-$163.7M

Solvency

Current ratio
7.72
Debt / Equity
0.03
Debt / Assets
0.03
CFO / Net profit
0.67
Cash / Market cap
63.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$9.7M
Gross profit$9.7M
Operating expenses$194.2M
Research and development$134.8M
Selling, general and administrative$59.4M
Operating income-$184.6M
Interest and other-$16.3M
Pretax income-$200.8M
Tax and other$43.3M
Net income-$244.1M

Revenue and net profit

Revenue fell 92.8% in FY2025; net profit is the dashed line.

Prothena Corporation plc revenue and net profit by fiscal year
Prothena Corporation plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$53.9M-$116.9M
FY2023$91.4M-$147.0M
FY2024$135.2M-$122.3M
FY2025$9.7M-$244.1M

Cash flows

FY2025: -$163.6M from operations, -$163.7M free after investment (dashed).

Prothena Corporation plc operating and free cash flow by fiscal year
Prothena Corporation plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$108.8M-$109.3M
FY2023-$133.9M-$136.7M
FY2024-$150.1M-$150.3M
FY2025-$163.6M-$163.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$9.7M-92.8%1Y
EBITDA
-$183.7M
Net profit
-$244.1M
Cash from operations
-$163.6M
Free cash flow
-$163.7M
Revenue CAGR, 3Y
-43.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$9.7M-$183.7M-$244.1M-$163.7M-87.0%-92.8%+99.6%

Monthly returns

Month-by-month returns of PRTA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$326.8M
Liabilities$46.3M
Equity$280.5M
Paid-in capital$1.6B
Retained earnings-$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PRTA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Prothena Corporation plc (this company)19.1x
  2. CTEV5.3x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Prothena Corporation plcPRTAthis company$484.3M-2.0x1.7x-87.0%-1.0x
Pacific Biosciences of California, Inc.PACB$506.3M-0.9x94.6x-10214.5%-7.5x
Arvinas, Inc.ARVN$499.4M-6.2x1.2x-18.6%-3.2x
AngioDynamics, Inc.ANGO$497.1M-14.6x2.7x-18.6%256.3x
Standard BioTools Inc.LAB$495.8M-6.6x1.2x-17.7%-4.7x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
The Oncology Institute, Inc.TOI$473.9M-7.8x-30.1x385.5%-12.8x
CTEVCTEV$470.0M——163.5%10.8x
OrthoPediatrics Corp.KIDS$464.9M-11.7x1.3x-11.4%-69.2x
Peer median—-6.6x1.2x-18.1%-4.2x

Year-to-date ROI

PRTA since 1 January, against earlier years.

Historical volatility

PRTA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Prothena Corporation plc operating margin by fiscal year
Prothena Corporation plc operating margin by fiscal year
DateOperating margin
FY2022-244.1%
FY2023-209.1%
FY2024-114.4%
FY2025-1906.6%
LineFY2025
Operating expensesOperating Expense$194.2M
Research and developmentResearch And Development$134.8M
Total expensesTotal Expenses$194.2M
Pretax incomePretax Income-$200.8M

Learn while you research

Academy chapters picked for Prothena Corporation plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →